learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
Search
forLearn
5 / 801 resultslearn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
learn unspecified lectican proteoglycans (nourkrin)
learn pyrrolidone carboxylic acid
learn glutamic acid
Research
5 / 1000+ resultsresearch The use of keratin biomaterials derived from human hair for the promotion of rapid regeneration of peripheral nerves
Keratin from human hair helps nerves heal faster.
research A Review of Keratin-Based Biomaterials for Biomedical Applications
Keratin from hair and wool is used in medical materials for healing and drug delivery.
research Regeneration of Peripheral Nerves Using Neuroinductive Biomaterial Scaffolds
Keratin biomaterials can effectively aid peripheral nerve regeneration and improve recovery.
research Neurosteroids Involved in Regulating Inhibition in the Inferior Colliculus
Neurosteroids help balance brain signals when certain inhibitions are reduced.
research A mechanism-informed deep neural network enables prioritization of regulators that drive cell state transitions
A new neural network helps identify key regulators in cell changes, aiding in understanding diseases and finding new treatments.
Community Join
5 / 1000+ resultscommunity What's going on with hmi115? The Phase 2 was concluded Nov2024 but no news
Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.
community My summation of PP405 - looks promising
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community PP405 (Non) Update - Feb 2025
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.